What is the recommended treatment for a severe chronic obstructive pulmonary disease (COPD) exacerbation?

Treatment for Severe COPD Exacerbation

For severe COPD exacerbations requiring hospitalization, immediately initiate short-acting bronchodilators, systemic corticosteroids (oral or IV, both equally effective), antibiotics if signs of bacterial infection are present, and noninvasive ventilation (NIV) if the patient has acute or acute-on-chronic respiratory failure with respiratory acidosis. 1

Core Pharmacological Treatment

Bronchodilators

• Administer short-acting beta-agonists and/or short-acting anticholinergics as first-line therapy
• These remain the foundation of acute symptom management despite limited placebo-controlled trial data 2
• Delivery method (nebulizer vs. metered-dose inhaler) can be chosen based on patient ability and institutional protocols

Systemic Corticosteroids

Use short-course, low-to-moderate dose corticosteroids for all hospitalized patients with severe exacerbations 1, 3

• Oral and intravenous routes are equally effective in most hospitalized patients—oral administration is preferred when feasible 3
• Short courses (5-7 days) are as effective as prolonged regimens while minimizing adverse effects like hyperglycemia and infections 3
• Blood eosinophil counts can predict responsiveness: eosinophilic patients experience shorter hospital stays and faster clinical improvement, while neutrophil-predominant or infectious exacerbations may derive less benefit 3
• In ICU settings, systemic corticosteroids reduce the need for invasive ventilation and shorten ICU stay 3

Antibiotics

Administer antibiotics to all patients admitted to the ICU with severe exacerbations 1, 4

• Approximately 50% of ICU-admitted patients have potentially pathogenic microorganisms 4
• Leading pathogens: Haemophilus influenzae, Streptococcus pneumoniae, followed by enterobacteria and Pseudomonas aeruginosa 4
• Appropriate empiric agents include:
  • Penicillins + beta-lactamase inhibitor
  • 2nd or 3rd generation cephalosporins
  • Carbapenems
  • Fluoroquinolones 4
• Adjust therapy based on sputum or endotracheal aspirate culture results 4
• For ambulatory patients, use antibiotics when clinical signs of bacterial infection are present 1

Critical Non-Pharmacological Interventions

Noninvasive Ventilation (NIV)

NIV should be used in hospitalized patients with acute or acute-on-chronic respiratory failure associated with respiratory acidosis 1

• NIV has greatly decreased mortality in exacerbations requiring ventilatory support 5
• Improves blood gases and pH, reduces hospital mortality, decreases requirements for invasive mechanical ventilation and intubation, and shortens hospital stay 6
• This is one of the most strongly evidence-supported interventions for severe exacerbations 7

Oxygen Therapy

• Provide supplemental oxygen for hypoxemic patients 1
• High-flow nasal cannula (HFNC) oxygen therapy is emerging but requires further prospective studies before routine recommendation 7

Early Pulmonary Rehabilitation

Initiate early pulmonary rehabilitation during hospitalization when associated with standard treatment 1, 7

• Recommended due to feasibility and safety 7
• Helps prevent rapid decline in health status and reduces readmission risk

Common Pitfalls and Caveats

Avoid These Mistakes:

• Do not use prolonged corticosteroid courses (>7 days)—they increase adverse effects without additional benefit 3
• Do not delay NIV in patients with respiratory acidosis—early initiation is critical for mortality reduction 6
• Do not withhold antibiotics in ICU patients even without clear bacterial signs—the guideline recommendation is strong for this population 1, 4

Treatment Intensity Guided by Severity:

• Assess for respiratory acidosis (pH), hypercapnia, and work of breathing to determine need for NIV
• Monitor for treatment failure and relapses, which are frequent across all severity levels 5
• Consider ICU admission for patients with severe respiratory distress, altered mental status, or inadequate response to initial therapy

Post-Exacerbation Management

View each severe exacerbation as a sentinel event requiring reassessment of long-term maintenance therapy 8

• The 2026 GOLD guidelines recognize that even a single moderate exacerbation increases future risk 8
• Optimize maintenance therapy post-discharge to prevent recurrence
• While biologics, macrolides, roflumilast, and ensifentrine have no role in acute management, they play important roles in exacerbation prevention as part of individualized maintenance strategies 8